TYK2 – Talk Bio

Actionable Insights Powered by AI

Alumis Files for IPO to Fund Phase 3 Studies for Second-Generation TYK2 Inhibitor

Alumis, IPO, TYK2 inhibitor, Phase 3 studies, immune-mediated diseases, biotech, precision immunology